Aytu Biopharma, Inc (AYTU) Stock Price & Analysis
Aytu Biopharma, Inc (AYTU) rose 0.00% to USD 2.16 as of July 25, 2026 at 04:40 UTC, according to Nexqual real-time market data.
AYTU last closed at USD 2.16; the session ranged USD 2.16–2.2 on volume of 10,374 shares. Market capitalization is $23.18M, with a 52-week range of USD 1.65–3.07 (NCM). Source: Nexqual, July 25, 2026 at 04:40 UTC.
Key Statistics (as of July 25, 2026 at 04:40 UTC)
| Price | USD 2.16 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 2.16 |
| Open | USD 2.19 |
| Day Range | USD 2.16 – 2.2 |
| 52-Week Range | USD 1.65 – 3.07 |
| Volume | 10,374 shares |
| Market Cap | $23.18M |
| Exchange | NCM |
Technical Analysis (AYTU)
Nexqual's technical model rates AYTU "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:40 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.77 (neutral) |
| vs SMA50 | Below (USD 2.19) |
| MACD | -0.02 (negative) |
Analyst Ratings (AYTU)
Wall Street analysts rate AYTU "Strong Buy" based on 3 analysts, with a mean price target of USD 9.5 (range USD 7–14.5), per Nexqual as of July 25, 2026 at 04:40 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 9.5 |
| High Target | USD 14.5 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (AYTU)
| EPS Estimate | USD -0.35 |
|---|---|
| Revenue Estimate | $12.28M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.41 vs est -0.43 ▲ beat |
| 2025-12-31 | USD -0.23 vs est -0.5 ▲ beat |
| 2025-09-30 | USD -0.09 vs est -0.2 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.06 ▼ miss |
Source: Nexqual, July 25, 2026 at 04:40 UTC.
Financials & Fundamentals (AYTU)
| Total Revenue | $56.60M |
|---|---|
| Revenue Growth (YoY) | -32.70% |
| Gross Margin | +64.78% |
| Operating Margin | -32.74% |
| Profit Margin | -60.17% |
| ROE | -97.42% |
| Debt / Equity | 65.27 |
| Current Ratio | 1.12 |
| Total Cash | $26.71M |
| Total Debt | $22.94M |
| Free Cash Flow | $-1.19M |
Source: Nexqual, July 25, 2026 at 04:40 UTC.
Financial Health Score (AYTU)
Nexqual rates Aytu Biopharma, Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:40 UTC.
| Growth | Critical — Revenue -18% YoY (annual), sharp decline |
|---|---|
| Profitability | Solid — Gross margin 65%, operating -33% |
| Balance Sheet | Solid — $27M cash vs $23M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$1M, burning cash |
| Efficiency | Critical — ROE -97%, ROA -3.7% |
Ownership (AYTU)
| Insider Ownership | +8.98% |
|---|---|
| Institutional Ownership | +36.77% |
| Shares Outstanding | 10.73M |
| Float | 7.63M |
| Short % of Float | +3.78% |
Source: Nexqual, July 25, 2026 at 04:40 UTC.
Leadership (AYTU)
Aytu Biopharma, Inc is led by Joshua R. Disbrow (age 50), CEO & Director, per Nexqual as of July 25, 2026 at 04:40 UTC.
| CEO & Director | Joshua R. Disbrow (age 50) |
|---|---|
| CFO, Corporate Secretary & Treasurer | Ryan J. Selhorn (age 43) |
| Vice President of Operations | Margaret Cabano |
| Senior Vice President of Scientific Affairs | Gerwin Westfield |
Major Backers & Investors (AYTU)
Notable institutional backers of Aytu Biopharma, Inc include Nantahala Capital Management, LLC, Stonepine Capital Management, LLC, AWM Investment Company, Inc., according to Nexqual as of July 25, 2026 at 04:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 10.13% |
| Stonepine Capital Management, LLC | 7.38% |
| AWM Investment Company, Inc. | 5.77% |
| Diadema Partners LP | 3.29% |
| Crown Advisors Management, Inc. | 1.35% |
| Two Sigma Investments, LP | 1.14% |
| Persistent Asset Partners Ltd | 0.87% |
| Renaissance Technologies | 0.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.76% |
| Geode Capital | 0.86% |
Source: Nexqual, July 25, 2026 at 04:40 UTC.
From Aytu Biopharma, Inc's Latest SEC 10-K Filing (filed 2025-09-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
- The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD.
- It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CODX | Co-Diagnostics, Inc. | USD 2.1 | ▼ 7.89% |
| AIM | AIM ImmunoTech Inc. | USD 0.25 | ▼ 0.4% |
| IBIO | iBio, Inc. | USD 1.43 | ▲ 3.62% |
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
| COCP | Cocrystal Pharma, Inc. | USD 0.9 | ▼ 4.24% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:40 UTC. This page is informational and not investment advice.